阿帕替尼在恶性肿瘤治疗中的研究进展

Progress in Apatinib for the Treatment of Malignant Tumor

血管生成与恶性肿瘤的发生、发展密切相关,已成为抗肿瘤治疗的一个靶点。阿帕替尼是一种新型小分子抗血管生成抑制剂,通过与血管内皮生长因子受体2结合,抑制肿瘤血管生成,发挥抗肿瘤作用。阿帕替尼首先在晚期胃癌的治疗上显示出良好的抗肿瘤效应及较好的耐受性,随着研究的进一步扩展,阿帕替尼在肺癌、乳腺癌、肝癌、肠癌、软组织肉瘤、卵巢癌、食管癌等肿瘤的治疗上也取得了较好的治疗效果,为恶性肿瘤的治疗提供了新的选择。

Angiogenesis is closely related to the occurrence and development of cancer,and it has become a target of anticancer therapy. Apatinib, a novel small-molecule vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor that may specifically bind vascular endothelial growth factor receptor 2, has demonstrated anticaneer activity by inhibiting tumor angiogenesis. Apatinib firstly showed good antitmnor effect and good tolerance in the treatment of advanced gastric cancer. With the further expansion of the study, apatinib also has demonstrated encouraging anticancer activity across a broad range of malignancies, including non-small-cell lung cancer,breast cancer,liver cancer, colon cancer, soft tissue sar- coma, ovarian cancer and esophageal cancer, which provides new options for the treatment of malignant tumors.